News

Company will also financially commit $15 million for those pursuing pharma manufacturing careers.

Joint initiative integrates submitted claims with parties’ platforms in effort to avoid duplicate data.

Company acquires Makara Health, who will work alongside Precision’s branded medical and scientific agency.

Merger with pharmacovigilance service provider helps company expands its end-to-end solutions in the region.

The collaboration—the parties say—can help improve supply chain operations.

Agency hopes to attract more seasoned expertise in manufacturing; also looking to add field inspectors.

Demands for services in this sector have increased since last year’s Q1 Scientific acquisition, CDMO says.

Bourgoin hub broadens customer needs to also address commercial manufacturing.

Network aims to improve end-to-end supply chain visibility for the life sciences industry.

Deal is expected to boost company’s market access capabilities.

Numbers point to a 2.9% boost over pre-pandemic records.

Manufacturing plant is expected to produce 500 million vaccine doses annually.

Deal is expected to offer airline with additional variety when it comes to shipping temperature-sensitive pharma products.

The latest people news happenings over the past month.

Senate committee report highlights a lack of visibility in API suppliers.

Amid continued tussling over drug costs, a new working group will review the government’s authority to revoke licenses for medical products.

Pharma Commerce offers a synopsis of some of the conference’s events.

Industry is still scrambling to handle clerical errors of DSCSA transactions.

Event—taking place in Indianapolis—places supply chain education at the forefront.

The Pulse online service will provide free resources to enable pharmacy to meet drug traceability rules.

Q&A explores new opportunities to strengthen supply chain resilience—and build on the lessons learned.

Project addresses customer demand in GMP-powered advanced therapeutics.

In an effort to strengthen supply chain, unnamed pharma company to use chain of custody application to combat an illegal global market worth up to $200 billion annually.

New site is expected to complement CDMO’s commercial production experience.

Acquisition expands company’s eCTD submission capabilities.

Latest investigation signals more scrutiny of pharmacy benefit managers and their role in treatment cost and coverage.

The deal—potentially totaling upwards of $100 million—strengthens the company’s selection of US generic prescription products.

Stats point to a 14.9% decline compared to January of last year.